Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies
Conditions
Interventions
Guadecitabine
Locations
21
United States
Roswell Park
Buffalo, New York, United States
Duke Cancer Center
Durham, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
Temple University
Philadelphia, Pennsylvania, United States
Center for Blood Cancers
Nashville, Tennessee, United States
Medizinische Universität Graz
Graz, Styria, Austria
Start Date
July 18, 2018
Primary Completion Date
October 4, 2021
Completion Date
October 4, 2021
Last Updated
August 27, 2024
NCT05564390
NCT03050268
NCT07320235
NCT06782542
NCT06439199
NCT05886049
Lead Sponsor
Astex Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions